Search
                    Psoriatic Arthritis Clinical Trials
A listing of 23  Psoriatic Arthritis  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 23
        
                There are currently 23 active clinical trials seeking participants for Psoriatic Arthritis research studies. The states with the highest number of trials for Psoriatic Arthritis participants are Florida, Texas, California and Ontario.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
                                
            
            
        Recruiting
                            
            
                The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Pa0016 50662, Gilbert, Arizona  +143 locations         
        
        
            Conditions: Psoriatic Arthritis
        
            
        
    
                
                                    Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
                                
            
            
        Recruiting
                            
            
                Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this sub-study are risankizumab and lutiki...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/11/2025
            
            Locations: Newport Huntington Medical Group /ID# 272764, Huntington Beach, California  +21 locations         
        
        
            Conditions: Psoriatic Arthritis
        
            
        
    
                
                                    A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
                                
            
            
        Recruiting
                            
            
                Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.
The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/30/2025
            
            Locations: AARR- Chandler AZ, Chandler, Arizona  +198 locations         
        
        
            Conditions: Psoriatic Arthritis
        
            
        
    
                
                                    A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
                                
            
            
        Recruiting
                            
            
                Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments.
The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/30/2025
            
            Locations: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ, Mesa, Arizona  +122 locations         
        
        
            Conditions: Psoriatic Arthritis
        
            
        
    
                
                                    Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
                                
            
            
        Recruiting
                            
            
                This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/24/2025
            
            Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama  +51 locations         
        
        
            Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
        
            
        
    
                
                                    A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/24/2025
            
            Locations: Ps0039 50140, Birmingham, Alabama  +15 locations         
        
        
            Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
        
            
        
    
                
                                    A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/17/2025
            
            Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona  +56 locations         
        
        
            Conditions: Psoriatic Arthritis, Overweight or Obesity
        
            
        
    
                
                                    Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
                                
            
            
        Recruiting
                            
            
                An open label phase 3 study             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/13/2025
            
            Locations: Sunpharma site no 50, Dothan, Alabama  +96 locations         
        
        
            Conditions: Psoriatic Arthritis
        
            
        
    
                
                                    Psorcast Mobile Study
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/06/2025
            
            Locations: Sage Bionetworks, Seattle, Washington         
        
        
            Conditions: Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
        
            
        
    
                
                                    A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
                                
            
            
        Recruiting
                            
            
                A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/23/2025
            
            Locations: Oregon Health and Science University, Portland, Oregon  +3 locations         
        
        
            Conditions: Psoriatic Arthritis, Spondyloarthritis, Axial
        
            
        
    
                
                                    Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
                                
            
            
        Recruiting
                            
            
                This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/06/2025
            
            Locations: M D Anderson Cancer Center, Houston, Texas         
        
        
            Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Enteropathic Arthritis, Enteropathic Spondylitis
        
            
        
    
                
                                    Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
                                
            
            
        Recruiting
                            
            
                While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                03/30/2025
            
            Locations: University of California, San Diego, San Diego, California         
        
        
            Conditions: Psoriatic Arthritis
        
            
        
    1 - 12 of 23
            